These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 27547865)

  • 1. Cancer and mTOR Inhibitors in Transplant Recipients.
    de Fijter JW
    Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P; Jouve T; Rostaing L
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors.
    Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
    Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
    Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation.
    Geissler EK; Schlitt HJ
    Kidney Int; 2010 Dec; 78(11):1075-9. PubMed ID: 20861822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality?
    Zuber J; Hermine O; Chatenoud L; Legendre C
    Curr Opin Organ Transplant; 2011 Dec; 16(6):606-13. PubMed ID: 21971509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
    Gutierrez-Dalmau A; Campistol JM
    Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
    De Simone P; Fagiuoli S; Cescon M; De Carlis L; Tisone G; Volpes R; Cillo U;
    Transplantation; 2017 Feb; 101(2):239-251. PubMed ID: 27495768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature.
    Bowman LJ; Brueckner AJ; Doligalski CT
    Transplantation; 2018 Feb; 102(2S Suppl 1):S50-S59. PubMed ID: 29369973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
    Barbari A; Maawad M; Kfoury Kassouf H; Kamel G
    Exp Clin Transplant; 2015 Oct; 13(5):377-86. PubMed ID: 26450460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.